Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

• Published in: Neuropsychiatric disease and treatment Vol. 13; pp. 1089 - 1097
• Main Authors: Yang, Fu De, Li, Juan, Tan, Yun Long, Liang, Wei Ye, Zhang, Rongzhen, Wang, Ning, Feng, Wei, Cai, Shangli, Zhuo, Jian Min, Zhang, Li Li
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2017; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Analysis; Antipsychotic agents; Antipsychotics; Care and treatment; Chinese; Complications and side effects; Dosage and administration; Drug dosages; Drug therapy; Medical Satisfaction Questionnaire; Mental disorders; Metabolism; Metabolites; Original Research; Paliperidone; Paliperidone ER; Patient satisfaction; Psychiatry; Psychosis; Psychotropic drugs; Quality of life; Questionnaires; Schizophrenia; China; Beijing China; patient satisfaction; paliperidone extended-release; Chinese; open label; schizophrenia; atypical antipsychotics; medical satisfaction questionnaire
• ISSN: 1176-6328; 1178-2021; 1178-2021
• DOI: 10.2147/NDT.S130483

The aim of this study was to evaluate the changes in treatment satisfaction after switching to paliperidone extended-release (ER) in Chinese schizophrenia patients dissatisfied with their previous antipsychotic treatment. In this 8-week, open-label, single-arm, multicenter, prospective study, 1,693 patients dissatisfied with previous antipsychotic medication were enrolled and switched to paliperidone ER tablets (3-12 mg/d) based on clinical judgment. The primary efficacy end point was change in Medication Satisfaction Questionnaire (MSQ) score from baseline to week 8. The secondary end points included percentage of patients with MSQ score ≥4, as well as changes in Clinical Global Improvement-Severity (CGI-S) and Personal and Social Performance (PSP) scores. MSQ scores increased significantly from baseline (mean [standard deviation {SD}]: 2.48 [0.55]) to week 8 (5.47 [0.89], <0.0001; primary end point, full analysis set). The percentage of patients with MSQ score ≥4 was 95.9% at week 8, indicating that most of the patients were satisfied with their treatment. Significant ( <0.0001) improvements from baseline to week 8 were noted in CGI-S score (2.37 [1.20]) and PSP score (25.5 [15.0]). A total of 174 (10.28%) patients experienced adverse events (AEs). The most common (>10 patients) events were extrapyramidal disorder (n=84, 4.96%), poor quality sleep (n=18, 1.06%) and akathisia (n=13, 0.77%). The majority of AEs were mild to moderate in severity. No deaths occurred. Treatment satisfaction improved after switching to paliperidone ER from the previous antipsychotic in Chinese patients with schizophrenia.